PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2015 Financial Results






SOUTH PLAINFIELD, N.J., July 16, 2015 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Firm will certainly host a webcast conference call to report its second quarter 2015 financial outcomes and give an update on the company’s company and outlook on Thursday, July 30, 2015 at 4:30 p.m. (ET) after the closing of the market.

The call can easily be accessed by dialing (877) 303-9216 (domestic) or + 1 (973) 935-8152 (international) 5 moments prior to the begin of the call and supplying the passcode 86272093. A live, listen-just webcast of the conference call can easily be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will certainly be readily available around 2 hrs after completion of the call and will certainly be archived on the company’s website for 2 weeks.

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical Firm focused on the discovery, progress and commercialization of orally administered, proprietary small molecule drugs targeting a spot of RNA biology we refer to as post-transcriptional control. Post-transcriptional regulate procedures are the regulatory events that occur in cells throughout and after a messenger RNA is copied from DNA through the transcription process. PTC’s internally found pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has actually found every one of its compounds currently under progress making use of its proprietary technologies. PTC strategies to keep on to create these compounds the 2 on its own and through selective collaboration arrangements along with best pharmaceutical and biotechnology companies. For a lot more article on the company, please visit our website www.ptcbio.com.

For a lot more Information:

Investors:
Emily Hill
+1 (908) 912-9327
ehill@ptcbio.com

Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

SOURCE PTC Therapeutics, Inc.

RELATED LINKS
http://www.ptcbio.com

Two techniques of temporal migraine surgery are ‘equally effective’

Two migraine surgery techniques targeting a individual “create site” are the 2 highly efficient in lowering the frequency and severity of migraine headaches, according to a randomized trial in the July issue of Plastic and Reconstructive Surgery®, the official medical diary of the American Society of Plastic Surgeons (ASPS).

Patients along with temporal-type migraine derive similar and considerable improvement from techniques that relieve tension on (decompression) or remove a section of (neurectomy) the nerve responsible for triggering their headaches, reports the study by ASPS Member Surgeon Bahman Guyuron, MD, Emeritus professor of plastic surgery at Case School of Medicine, Cleveland, and colleagues.

Both Approaches efficient for Temporal Migraine Surgery

Dr. Guyuron made the migraine surgery techniques after noticing that some migraine patients had reasonable headache activity after undergoing cosmetic forehead lift procedures. The surgery targets create sites in the nerve branches that develop headaches, identified by preoperative evaluation. create sites are detected using a constellation of symptoms, nerve blocks, ultrasound Doppler and CT scans.

The study included twenty patients along with the temporal sort of migraine headaches — one of both most common create sites. All of had serious and regular migraine attacks despite standard medications. The patients underwent surgery on the 2 sides of the head, targeting the nerve implicated in temporal migraine headaches: the zygomaticotemporal branch of the trigeminal nerve (ZTBTN).

On one side, a decompression procedure was performed to relieve tension placed on the nerve by surrounding tissues. On the others side, a neurectomy procedure was performed, in which a small piece of the nerve was removed. Neurectomy of the ZTBTN has actually long been performed as portion of several plastic and neurosurgery procedures for decades, along with no apparent complications.

To assess the relative effectiveness of both techniques, outcomes were compared between sides one year after surgery. In nearly 90 percent of operated sites, surgery made at least a one-half reduction in migraine frequency, days along with migraine, and headache severity and duration.

The outcomes were almost identical between sides. Migraine frequency decreased from 14.6 to 2.2 per month along with nerve decompression and from 14.2 to 1.9 per month along with neurectomy. Migraine severity (on a ten-point scale) decreased from 7.0 to 2.9 along with decompression and from 6.8 to 2.6 along with neurectomy.

Both techniques additionally reasonable migraine-related disability. There were no complications of either procedure.

Migraine surgery has actually emerged as an efficient option for patients that don’t respond to the limited medication selections for treating migraine headaches. Due to the fact that 2000, Dr. Guyuron and his group have actually published 24 articles in peer-reviewed journals on migraine surgery and its efficacy, along with an additional 12 research projects in process. 5 independent centers have actually confirmed Dr. Guyuron’s findings.

The brand-new trial adds to the evidence by showing that decompression and neurectomy are “just as effective” techniques for treatment of right patients along with temporal migraine headaches. Dr. Guyuron and colleagues conclude, “the 2 procedures can easily be performed safely along with considerable improvement in symptom burden, devoid of concern for excellent morbidity [complications].” They include that patients that don’t grab adequate relief from very first decompression surgery could still incentive from neurectomy as a second option.

Story Source:

The above short article is reprinted from materials offered by Wolters Kluwer Health: Lippincott Williams and Wilkins. Note: contents could be edited for content and length.

Medical tourism: Implications for patients, health systems

Patients that travel abroad for medical treatment risk returning along with complications or infections that require costly treatment on the NHS and is one of the troubles highlighted in a brand-new handbook exploring medical tourism.

In particular, cosmetic procedures appear a location of growth for medical travel by UK patients, however can easily frequently result in costly intervention as soon as spine home, researchers at the University of York have actually concluded.

It’s estimated that botched cosmetic job overseas costs the NHS £8 million a year.

Medical tourism — individuals taking a trip abroad along with the expressed purpose of accessing medical treatment — is a growing phenomenon associated along with globalization.

This growth has actually been boosted by cheaper air travel and by the Internet, which allows medical providers from one country to market themselves to patients in another.

It is estimated that in 2015 globally 5 million individuals will certainly seek medical treatment abroad.

However, little is known as to which patients go for to travel and why, as soon as others do not.

Researchers from York’s department of Social Policy and Social job and the London School of Hygiene and Tropical Medicine brought with each other a global community of researchers and writers to make the ‘Handbook on Medical Tourism and Patient Mobility’. It is published by Edward Elgar.

One of the handbook’s editors, Dr Neil Lunt, said: “We have actually been aware of a growing worldwide group of scholars that are interested in patients that travel from country for treatment.

“Just what we wanted to do in this handbook was actually to bring with each other every one of the scholars however additionally to concentrate on places and writers that are pretty frequently neglected.

“frequently the focus is on the US and Europe, however there’s crucial points going on about the globe in Africa, Asia, Middle East and South America.”

The handbook explores the emergence of medical tourism and patient mobility and the implications this has actually for patients and healthiness units about the world.

It explores topics such as risk, law and ethics; patient experience and treatment outcomes for cosmetic, transplantation, dental, fertility and fat burning surgery.

The editors conclude that despite a number of studies focusing on UK patients, there has to be further research on the potential impact and costs of medical tourism on the NHS.

Neil Lunt added: “If a person decides to go oversees for cosmetic work, that’s an specific thing they do. however if as soon as they return there’s job that has to be done, that usually gets selected up by the NHS.

“individuals are travelling abroad devoid of necessarily knowing that if goes wrong they are not covered in the same method in terms of redress if they were treated by the NHS or treated privately in the UK. individuals are so used to merely jumping on planes.”

More article can easily be found at: https://www.elgaronline.com/view/9781783471188.xml

Story Source:

The above short article is reprinted from materials offered by University of York. Note: contents could be edited for content and length.

El ‘gen autolimitante’ de Oxitec podría ayudar a controlar la polilla invasiva






OXFORD, Inglaterra, July 16, 2015 /PRNewswire/ —

– El ‘gen autolimitante’ de Oxitec podría ayudar a controlar la polilla invasiva sin tener que utilizar pesticidas    

Una nueva forma ecológica y libre de pesticidas de controlar las plagas de insectos se ha conocido hoy con la publicación de los resultados científicos que muestran que la polilla de la col de Oxitec (DBM) con un ‘gen autolimitante’ puede reducir drásticamente poblaciones de DBM, una especie invasiva y problema grave para los cultivos de col, col rizada, canola y otros cultivos crucíferos.

Publicados en la revista BMC Biology, los resultados de hoy ofrecen otra prueba de concepto de éxito para el nuevo enfoque desarrollado por Oxitec, una compañía derivada de la Oxford University pionera en métodos sin pesticidas para controlar las poblaciones de insectos dañinos. La técnica del gen autolimitante ya se ha probado con los mosquitos que portan la fiebre del dengue, reduciendo con éxito sus poblaciones en más del 90% en Brasil, Panamá y las Islas Caimán, un nivel sin precedentes de regulate por cualquier método, y uno que está conduciendo a proyectos municipales tras la aprobación por el grupo de bioseguridad nacional en Brasil para su lanzamiento por todo el país.

Este enfoque se inspiró en la Sterile Insect Procedure (SIT), que se ha utilizado en todo el mundo durante más de 50 años, donde los insectos macho están esterilizados por radiación y se sueltan para aparearse con hembras dañinas. Sin descendencia, la población cae. El enfoque de Oxitec aprovecha los instintos reproductivos naturales de los insectos macho, pero no se basa en la radiación para esterilizarlos, lo que puede afectar a muchos genes y a la capacidad del insecto para aparearse. En lugar de ello, se utiliza un gen autolimitante portado por los insectos, en este caso la polilla de la col. Las polillas macho con este gen se sueltan para aparearse con las hembras dañinas, y dado que la supervivencia de la hembra no sobrevive para reproducirse, el número de polillas dañinas disminuye. Las polillas de Oxitec también llevan un marcador de color para su supervisión.

En los nuevos resultados publicados hoy, los científicos de EE. UU., Reino Unido y China muestran que las poblaciones de polillas de la col en invernaderos fueron controladas en ocho semanas.

A diferencia de los insecticidas, que pueden afectar a una amplia variedad de insectos, incluyendo abejas y otros insectos beneficiosos, este enfoque es totalmente específico por especie, de modo que solo afecta a la población dañina objetivo. El gen autolimitante es además no tóxico, de modo que si las aves u otros animales se comen las polillas no sufrirán efectos secundarios.  

“Esta investigación está abriendo nuevas puertas para el futuro de la agricultura con métodos de regulate de plagas que no son tóxicos ni tienen pesticidas”, dijo el physician Neil Morrison, científico de investigación de DBM en Oxitec y coautor del documento. “Todos compartimos un interés en el regulate de plagas seguras y ecológicas, de modo que es una herramienta muy prometedora a la que los agricultores podrían dar un buen uso como parte de las estrategias de gestión de plagas integradas (IPM) para una agricultura saludable y sostenible”.

El coautor Tony Shelton, profesor de Entomología en la Cornell University, es también un experto en IPM, y espera que la nueva tecnología pueda utilizarse como parte de más sistemas de agricultura agro-ecológica, incluyendo producción orgánica. “Tanto los pesticidas convencionales como orgánicos fallan al regulate la DBM, de modo que es momento para que los científicos y agricultores trabajen juntos para encontrar nuevas herramientas”, dijo.

La lucha con la polilla de la col para la producción de vegetales crucíferos cuesta a los agricultores de todo el mundo hasta 5.000 millones de dólares cada año. La DBM está escasamente controlada por los métodos actuales, especialmente cuando las polillas están haciéndose cada vez más resistentes a los insecticidas.

“La polilla de la col es un problema grave para los agricultores del estado de Nueva York y de todo el mundo, allí donde haya vegetales crucíferos y cultivos de campo. Estas polillas invaden y atacan los cultivos, y están desarrollando resistencia a los insecticidas, de manera que necesitamos urgentemente nuevas herramientas para controlarlos mejor”, añadió el profesor Shelton, que está planeando estudios de seguimiento para probar las polillas de Oxitec bajo condiciones externa y más duras en el norte de Nueva York.

Estos estudios incluyen análisis de campo este verano, con planes de lanzamiento de campo a pequeña escala en el futuro. Los próximos ensayos ya se han aprobado por el Departamento de Agricultura de EE. UU. (USDA) tras una extensa revisión por expertos independientes y una consulta pública el año pasado.

El physician Morrison de Oxitec concluyó: “Mientras los retos agrícolas hacen que la coexistencia de diversos métodos de regulate de pestes sea cada vez más importante, los agricultores necesitarán más que nunca el apoyo de sus gobiernos, el público y la comunidad científica para ayudar a ofrecerles las herramientas que necesitan para llevar la comida a nuestras mesas”.

Para ver el documento de acceso libre, ‘Pest regulate and resistance administration with launch of insects carrying a male-deciding on transgene’, publicado en BMC Biology, visite:

http://dx.doi.org/10.1186/s12915-015-0161-1

Acerca de Oxitec   

Oxitec es pionera en el uso de ingeniería genética para controlar plagas de insectos que transmiten enfermedades y dañan cultivos, y fue fundada en 2002 como una empresa derivada de la Universidad de Oxford (RU).

Acerca de la polilla de la col 

La polilla de la col (DBM) es el peor insecto del mundo para cultivos como la col, canola, brócoli, coliflor y col rizada. Esta polilla no está suficientemente controlada por los enemigos naturales u oras prácticas de gestión pesticide integradas, de manera que los agricultores suelen pulverizar sus cultivos muchas veces con insecticidas. Esto ha llevado a la DBM a desarrollar Resistencia a la mayoría de los insecticidas. Hay también una creciente preocupación por los residuos de los pesticidas en los cultivos, para la seguridad del trabajador y posibles riesgos al medio ambiente, de forma que se necesitan nuevos enfoques.

Preguntas frecuentes sobre Diamondback Moth y vídeo en el sitio web de Oxitec: http://www.oxitec.com/dbm                                                        

Página DBM del profesor Shelton en Cornell University: http://bit.ly/1Cd9CYZ

Para más información:   

Sitio: http://www.oxitec.com/dbm

Facebook: http://www.facebook.com/oxitec  

Twitter: http://www.twitter.com/oxitec

Contacto de prensa:
Chris Creese
info@oxitec.com
+44(0)1235-832393

SOURCE Oxitec

Study finds variation in rates of secondary cleft lip, palate surgery

For youngsters along with cleft lip and palate, the possibilities of undergoing secondary surgery vary depending on the focus where they’re treated, reports a study in Plastic and Reconstructive Surgery — Global Open®, the official open-access medical diary of the American Society of Plastic Surgeons (ASPS).

When secondary surgeries are performed, they don’t necessarily boost the child’s last facial appearance, according to the brand-new research by ASPS Member Surgeon Dr. Thomas J. Sitzman of Cincinnati Children’s Hospital Medical focus and colleagues.

Secondary Cleft Lip and Palate Surgery — Variation and Outcomes

The researchers analyzed 130 youngsters undergoing surgery to repair cleft lip and cleft palate at four specialized centers. The patients were portion of the “Americleft” study, made to compare surgical outcomes across North American cleft palate centers. Every one of patients had cleft lip/cleft palate as their just abnormality, unrelated to any kind of congenital syndrome.

Rates of secondary surgeries — added procedures performed on the lip, palate, and/or nose after the very first (primary) surgery — were compared across the study centers. Many patients were followed up through adolescence.

The outcomes showed substantial variation in rates of secondary lip surgery and secondary nasal surgery (rhinoplasty) at the four cleft palate centers. Through 10 years, the estimated Fee of secondary lip surgery by focus ranged from 5 percent to 60 percent. There was likewise substantial variation in rates of secondary rhinoplasty — from 47 to 79 percent by age twenty years.

Overall, the risk of secondary lip surgery varied 12-fold across centers, while the risk of secondary rhinoplasty varied six-fold. There was no substantial variation in secondary palate surgery.

Surgeon ratings of follow-up photographs discovered no substantial distinction in the last appearance of the nose and lip for patients that had secondary surgery versus primary surgery only. (The researchers emphasize that secondary surgery could have actually improved outcomes for some children, despite the fact that there was no overall distinction in between groups.)

Secondary surgery for cleft lip and palate adds to the “burden of care” in terms of ache and fear for youngsters and time off job for parents, too as better healthcare costs. The outcomes are consistent along with a previous European study (Eurocleft) reporting variations in secondary surgery rates.

“This study improves the crucial question of why variation exists in between centers in the usage of secondary surgery,” Dr. Sitzman and colleagues write. It could be that some centers achieve much better outcomes along with the very first surgery, or that centers have actually various thresholds for recommending further surgery. The researchers note that their study didn’t contain photos to assess the outcomes of the primary surgery.

But regardless of the source of the variation, “The effect is broad differences in a child’s burden of surgical care depending upon where they are treated,” Dr. Sitzman and coauthors write. They call for further studies to much better define the role of secondary surgery for youngsters along with cleft lip and palate.

Story Source:

The above guide is reprinted from materials given by Wolters Kluwer Health: Lippincott Williams and Wilkins. Note: contents could be edited for content and length.